Lannion,
LUMIBIRD MAINTAINS DOUBLE-DIGIT PRO FORMA GROWTH1 IN 2021
Consolidated revenues (unaudited)
Revenues (€m) | 2021 | 2020 | Reported change | pro forma 2020 1 | Pro forma 1 change |
First quarter | 33.8 | 21.9 | +54% | 32.7 | +3.2% |
Second quarter | 41.7 | 23.9 | +75% | 33.8 | +23% |
Third quarter | 37.2 | 32.7 | +13% | 32.8 | +13% |
Fourth quarter | 49.8 | 48.2 | +3% | 48.3 | +3% |
12 months | 162.5 | 126.7 | +28% | 147.7 | +10% |
of which | |||||
Photonics | 76.3 | 68.8 | +11% | 68.8 | +11% |
Medical | 86.1 | 57.9 | +49% | 78.8 | +9% |
The LUMIBIRD Group’s consolidated full-year revenues came to €162.5m in 2021, up 28% based on reported data and +10% pro forma1. At constant exchange rates, growth came to +29%, after offsetting negative exchange effects for €1.5m. On a pro forma basis, the Group achieved strong full-year growth across both of its divisions, with +11% for Photonics and +9% for Medical.
For the Photonics division, the last quarter was marked by:
- the robust trends maintained for the Industrial and Scientific business (+16% to €8.5m), driven by the OEM activities for flat screen and medical applications. This segment recorded €33.9m of full-year revenues, up 35%;
- A contraction in the Defense / Space business (-38% to €5.5m), reflecting the planned scaling down of contract deliveries, partially offset by the growth in non-contract sales. Over the year, Defense / Space revenues came to €20.0m, down 7%;
- The continued upturn in the Lidar business (+17% to €9.7m), and especially Lidar systems, catching up the delay sustained during the first half of the year. As announced, the Lidar segment ended the year with a slight increase in annual revenues (+1% to €22.4m).
With 10% pro forma growth in the fourth quarter, and full-year growth of 49% based on reported data and +9% pro forma, the Medical division confirmed the successful integration of Ellex in 2021, characterized by the rapid activation of major commercial synergies. In 2021, these made it possible to ramp up the penetration of Quantel Medical’s products on the world’s top two markets for this sector:
Next date:
2021 full-year results on
Born from the combination of
Contacts
Chairman and CEO Tel. +33(0) 1 69 29 17 00 info@lumibird.com | Aude Nomblot-Gourhand Secretary General – CFO Tel. +33(0) 1 69 29 17 00 info@lumibird.com | Calyptus Investors Relations Tel. +33(0) 1 53 65 37 91 lumibird@calyptus.net |
1 Including the acquisitions from 2020 (Ellex and Esmed) at
2 EBITDA corresponds to income from ordinary operations restated for provisions and depreciation, net of reversals and expenses covered by such reversals.
Attachment
- 220124_Lumibird_CAt4_2021EN
![](https://ml-eu.globenewswire.com/media/MDU4NDg1ODgtNjA1Ni00MDFjLWI1ZTUtY2M1OWZhMDg2OTQxLTEyMDg4NDM=/tiny/Lumibird-SA.png)
© OMX, source